BBC Doctor's Blood‑Test Lab Faces ASA Ban for Misleading Claims Rangan Chatterjee's Do Health blood‑testing service has been barred by regulators after adverts claimed it could diagnose or prevent serious diseases without evidence, raising questions about celebrity‑led health ventures. Rangan Chatterjee, a familiar voice on BBC Breakfast and the successful host behind the Feel Better, Live More podcast, has found himself in the midst of a regulatory controversy that questions the integrity of his latest venture. The British healthcare entrepreneur is being accused of misleading the public with advertising that claimed his blood‑testing service could detect and even prevent serious conditions such as Alzheimer's disease, diabetes and other chronic illnesses. The Advertising Standards Authority (ASA), the body that oversees advertising in the United Kingdom, has banned the adverts in question after concluding that the firm could not provide evidence to support its extraordinary claims.Do Health Offers Annual Blood Testing SubscriptionDo Health, the company behind the disputed service, offered a £249 annual subscription that includes a series of blood bottles and a one‑on‑one conversation with a personal health coach. In a series of posts on Facebook and LinkedIn, Chatterjee promoted the product while also sharing anecdotes about his father's long‑term battle with a chronic autoimmune disease that required dialysis for fifteen years.He stated, 'I've had a father who got chronically unwell, got an autoimmune disease, and was on kidney dialysis for 15 years. I don't want that for me.' The ASA interpreted the messaging as implying that the blood tests could identify such a condition early and prevent its progression, a claim the company could not substantiate. Under British law, advertising must be truthful and not mislead consumers. The ASA's ruling highlighted that without objective evidence confirming the tests' diagnostic or preventive capabilities, the advertisements were considered deceptive.Regulator Rejects Do Health Advertising DefenceDo Health's defence argued that Chatterjee's posts were comments about healthcare rather than direct paid advertising and that his personal references were meant to illustrate the importance of preventative care. The regulator rejected both arguments, concluding that the posts effectively promoted a product he had co‑founded and that the promised benefits were not backed by scientific data. Chatterjee said the situation was a misunderstanding, but the consequences for his brand have already begun to emerge.Media reports have cast a shadow over his previous work; while the Feel Better, Live More podcast remains popular, the controversy has prompted calls from several health‑policy experts for clearer regulation of wellness offerings marketed to the general public. The case also raises broader questions about the role public‑facing medical personalities have in influencing health choices without rigorous scientific endorsement. The regulatory decision has unfolded against a backdrop of other local celebrities grappling with public perception.Comic actor Josh Widdicombe, recently participating in Strictly Come Dancing, shared a light‑hearted but uncomfortable anecdote about returning late to his home with no key access, underscoring his ongoing connection to daily life. Meanwhile, actress Madeline Smith revealed a family drama involving her late husband who once fired a gun in a doorway. In the theatrical world, playwright Suzie Miller has reopened the storyline of her acclaimed production to better reflect the experiences of black families.Various Celebrities Share Recent Personal StoriesRoyal fundraising events continue to draw attention; Rowan Atkinson's son attended a charity gala wearing formal attire, while the British Museum Ball featured a protest about the return of the Elgin Marbles. These varied stories illustrate a media landscape where personal experiences, public personalities, and regulatory oversight intersect.The Rangan Chatterjee case, in particular, serves as a reminder that even well‑known figures in health and entertainment must navigate stringent ethical and regulatory frameworks, especially when monetising claims about medical diagnostics and preventive care. The outcome of the ASA's decision may set a precedent for how future wellness businesses present their services and the responsibilities that come with influencing public health decisions.